Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
02 mai 2022 22h44 HE
|
Wesana Health
CHICAGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the...
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
18 avr. 2022 18h34 HE
|
Wesana Health
Concurrently, the Company is launching a non-brokered private placement NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CHICAGO and TORONTO, April 18, 2022...
Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events
29 mars 2022 07h30 HE
|
Wesana Health
CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing...
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
22 mars 2022 07h30 HE
|
Wesana Health
CHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing...
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
14 mars 2022 09h07 HE
|
Wesana Health
CHICAGO and TORONTO, March 14, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing...
Wesana Provides Updates on Build-out of Third Clinic
11 mars 2022 17h00 HE
|
Wesana Health
CHICAGO and TORONTO, March 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing...
Wesana Health Appoints Meghna A. Gaeta as Chief Marketing Officer
25 janv. 2022 07h30 HE
|
Wesana Health
CHICAGO and TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing...
Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol
18 janv. 2022 07h30 HE
|
Wesana Health
Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol,...
Wesana Health Provides Strategic and Operational Updates
12 janv. 2022 07h00 HE
|
Wesana Health
Wesana granted pre-IND meeting with FDA, currently set for March 11, 2022Wesana Clinics exhibited a record quarter of billings, new patient visits, telemedicine utilization, overall patient...
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
11 janv. 2022 07h00 HE
|
Wesana Health
CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing...